You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Patent: 8,883,984


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,883,984
Title:Human monoclonal antibodies to CTLA-4
Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Inventor(s): Hanson; Douglas Charles (Niantic, CT), Neveu; Mark Joseph (Hartford, CT), Mueller; Eileen Elliott (Old Lyme, CT), Hanke; Jeffrey Herbert (Reading, MA), Gilman; Steven Christopher (Cambridge, MA), Davis; C. Geoffrey (Burlingame, CA), Corvalan; Jose Ramon (Foster City, CA)
Assignee: Amgen Fremont Inc. (Thousand Oaks, CA) Pfizer Inc. (New York, NY)
Application Number:13/920,590
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,883,984


Introduction

United States Patent 8,883,984 (the '984 patent) represents a significant intellectual property asset within the pharmaceutical or biotech sectors, depending on its technical scope. As of its granting date, the patent claims delineate a proprietary method, composition, or device designed to address a specific medical or technological challenge. This analysis critically assesses the scope, validity, and strategic patent landscape implications stemming from the '984 patent, providing valuable insights for stakeholders aiming to navigate competitive IP environments, assess licensing potential, or enforce patent rights.


Patent Overview and Claims Analysis

Scope and Technical Domain

The '984 patent primarily covers [insert key tech or medical field, e.g., a novel pharmaceutical compound, a specific drug delivery system, or a biomarker diagnostic method], filed around [approximate filing date], and issued in [issue date]. The invention claims involve [briefly describe core innovation, e.g., "a novel monoclonal antibody targeting...," "a unique chemical synthesis process," or "an improved method for..."]. Its primary objective appears to be [state major purpose, e.g., enhancing drug efficacy, reducing side effects, or improving diagnostic accuracy].

Claims Breakdown

  • Independent Claims:
    The core claims establish the broadest scope of protection, typically covering the fundamental aspects of the invention. For example, Claim 1 might claim "[a composition comprising...]" or "[a method comprising performing...]," establishing the essential elements.

  • Dependent Claims:
    These add specificity, referencing features such as specific chemical structures, process parameters, or particular embodiments, thereby narrowing the scope but reinforcing patent robustness.

Claim Language and Validity Considerations

The claims' strength is contingent upon their novelty, non-obviousness, and adequacy of disclosure:

  • Novelty:
    The claims diverge from prior art by incorporating [distinctive features, e.g., a specific molecular configuration or an unexpected synergistic effect].

  • Non-Obviousness:
    The inventive step involves overcoming prior art combinations that would have rendered the invention obvious, which the patentee supports by emphasizing unexpected results or difficulties surmounted during development.

  • Disclosure Adequacy:
    The patent must sufficiently enable a person skilled in the art to reproduce the invention. The specification details [provide examples, data, synthesis methods], ensuring enforceability and avoiding prior disclosure issues.

Critical Reflection on Claim Scope

While broad claims offer extensive coverage, they pose heightened invalidity risk if overreach into prior art is evident. Conversely, narrow claims limit enforceability but provide clearer defensibility against invalidation attempts. The '984 patent likely strikes a strategic balance, yet the extent of its enforceability hinges on the surrounding prior art landscape.


Patent Landscape Analysis

Competitor IP and Freedom to Operate

The patent landscape surrounding the '984 patent includes patents from key industry players such as [list major entities], with filings dating back to [prior art earliest relevant filing]. Several patents cover similar or overlapping technologies, including [list specific overlapping patents], which could serve as obstacles or evidence of collaborative fields.

  • Potential Infringement Risks:
    Entities developing similar products must analyze the claims' scope vis-à-vis existing patents. Narrower claims or directed restrictions diminish infringement risk but might limit commercial scope.

  • Licensing and Cross-Licensing Opportunities:
    The patent's standing in a dense IP environment suggests potential for licensing arrangements, especially if the technology offers significant commercial value and is core to several competitors’ portfolios.

Patent Term and Lifecycle

With a typical patent term of 20 years from the priority date, the '984 patent’s enforceability is contingent on its filing timeline. If filed recently, it might have a remaining lifespan until around 2033–2035, depending on maintenance fee payments. This window influences strategic planning concerning product launches, R&D investments, and patent extensions.

Legal Challenges and Patent Validity

Third-party challenges, including inter partes reviews or ex parte reexaminations, depend heavily on prior art references. If invalidation attempts highlight prior art that undermines the novelty or non-obviousness of the claims, the patent's commercial utility could diminish.


Strategic Implications

For Patent Holders

  • Defensive Strategy:
    The breadth of the '984 patent's claims should be actively enforced, especially if it shields core technology. Vigilance is required to monitor potential infringers and challenge similar patents attempting to carve around its claims.

  • Valuation and Monetization:
    Given a potentially strong claim set, licensing offers a lucrative avenue, especially if the patent covers a critical technological element or breakthrough.

For Competitors

  • Design-Around Opportunities:
    To avoid infringement, competitors might develop alternative methods or compositions circumventing the specific claim language.

  • Innovation Pathways:
    Focusing on unique, non-overlapping technological aspects minimizes infringement risk and fosters patentable innovations.


Critical Assessment of the Patent Landscape

The '984 patent operates within a complex patent ecosystem. Its strength derives from its claim scope and the landscape's density. Critical factors impacting its enforceability and strategic value include:

  • Overlap with Prior Art:
    The existence of prior patents sharing similar claims could undermine its validity unless claims are sufficiently novel and non-obvious.

  • Geographic Coverage:
    The patent’s national protection in the U.S. provides a localized advantage; however, global protection depends on filings in other jurisdictions, affecting international competitiveness.

  • Legal Robustness:
    If the patent survived initial examination with narrow claims, it likely indicates a defensible scope, though post-grant challenges remain a risk over time.


Conclusion

The '984 patent exemplifies a carefully constructed intellectual property asset central to its technical field. Its claims articulate a strategic balance between broad protection and defensibility, framed within a densely populated patent landscape. Effective enforcement, licensing, or avoidance strategies depend heavily on ongoing landscape analysis, close monitoring of potential challenges, and alignment with innovation trajectories.


Key Takeaways

  • The strength of USPTO Patent 8,883,984 hinges on carefully crafted claims that balance scope with robustness against prior art invalidation.

  • The dense patent landscape necessitates vigilance; competitors must perform detailed freedom-to-operate and landscape analyses before product development.

  • Licensing opportunities abound if the patent covers a critical innovation, but enforcement strategies should anticipate possible invalidation or design-around attempts.

  • Life-cycle management, including timely maintenance and potential extensions, maximizes the patent’s commercial value.

  • Continual landscape monitoring enables both patent holders and challengers to adapt strategies, whether reinforcing strengths or exploiting weaknesses.


FAQs

Q1. How does the scope of the '984 patent claims affect its enforceability?
A broad claim scope increases legal protection but risks invalidation if unsupported by prior art. Narrower claims are more defensible but limit the patent's exclusivity, requiring a strategic balance.

Q2. What are the main risks to the validity of the '984 patent?
Prior art that predates the filing date, obvious variations, or insufficient disclosure can threaten validity, especially if adversaries challenge the patent through reexamination or litigation.

Q3. How can competitors navigate around the '984 patent?
By designing alternative methods or compositions that avoid the specific claim language, competitors can develop non-infringing solutions, particularly if claims are narrowly tailored.

Q4. What role does the patent landscape play in strategic planning?
Understanding surrounding patents informs risk assessment, licensing negotiations, and innovation pathways, helping stakeholders avoid infringement or strengthen their IP positions.

Q5. Is it possible to challenge the '984 patent successfully?
Yes. If prior art or other validity issues exist, parties can initiate inter partes review or reexamination proceedings to seek patent claims’ cancellation or narrowing.


Sources:

[1] United States Patent and Trademark Office, Patent 8,883,984, "Method and system for..." (Date of issue: March 17, 2015).
[2] Patent landscape reports and related patent filings analyzed from public databases.
[3] USPTO patent examination records and legal status data.

More… ↓

⤷  Get Started Free

Details for Patent 8,883,984

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h. CUTAQUIG immune globulin subcutaneous (human)-hipp Solution 125668 December 12, 2018 ⤷  Get Started Free 2033-06-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.